• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Atlantic Coastal Acquisition Corp. II filed SEC Form 8-K: Regulation FD Disclosure

    11/13/24 5:21:02 PM ET
    $ACAB
    Blank Checks
    Finance
    Get the next $ACAB alert in real time by email
    8-K
    false 0001893219 0001893219 2024-11-13 2024-11-13 0001893219 dei:FormerAddressMember 2024-11-13 2024-11-13 0001893219 us-gaap:WarrantMember 2024-11-13 2024-11-13 0001893219 us-gaap:CommonClassAMember 2024-11-13 2024-11-13

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): November 13, 2024

     

     

    ABPRO HOLDINGS, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-41224   87-1013956

    (State or Other Jurisdiction

    of Incorporation)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification No.)

     

    68 Cummings Park Drive

    Woburn, MA

      01801
    (Address of principal executive offices)   (Zip Code)

    1-800-396-5890

    (Registrant’s telephone number, including area code)

    Atlantic Coastal Acquisition Corp. II

    6 St Johns Lane, Floor 5

    New York, NY 10013

    (Former name or former address, if changed since last report.)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240-13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of Each Class

     

    Trading
    Symbol(s)

     

    Name of Each Exchange

    on Which Registered

    Shares of Series A common stock, par value $0.0001 per share   ABP   The Nasdaq Stock Market LLC
    Warrants, each whole warrant exercisable for one share of Series A common stock at an exercise price of $11.50   ABPWW   The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     


    Item 7.01.

    Regulation FD Disclosure.

    On November 13, 2024, Abpro Holdings, Inc. (f/k/a Atlantic Coastal Acquisition Corp. II) (the “Company”) issued a press release attached as Exhibit 99.1 announcing the closing of the previously announced Business Combination between Atlantic Coastal Acquisition Corp. II and Abpro Corporation. The Company expects that its common stock will begin to trade on The Nasdaq Global Market under the symbol “ABP” and its public warrants will begin to trade on The Nasdaq Capital Market under the symbol “ABPWW”, on or about November 13, 2024.

    The foregoing (including Exhibit 99.1) is being furnished pursuant to Item 7.01 and will not be deemed to be filed for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise be subject to the liabilities of that section, nor will it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.

     

    Item 9.01.

    Financial Statements and Exhibits.

    (d) Exhibits

     

    Exhibit

    No.

       Description
    99.1    Press Release dated November 13, 2024
    104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    ABPRO HOLDINGS, INC.
    By:  

    /s/ Ian Chan

    Name:  

    Ian Chan

    Title:   Chief Executive Officer

    Dated: November 13, 2024

    Get the next $ACAB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ACAB

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ACAB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Atlantic Coastal Acquisition Corp. II Receives Notification of Deficiency from Nasdaq Related to Delayed Quarterly Report on Form 10-Q

      NEW YORK, June 13, 2024 /PRNewswire/ -- Atlantic Coastal Acquisition Corp. II (NASDAQ:ACAB) (the "Company"), a special purpose acquisition company, announced that it had previously received written notification (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") on June 3, 2024 that, because the Company had not yet filed its Quarterly Report on Form 10-Q for the three month period ended March 31, 2024 (the "10-Q") with the Securities and Exchange Commission (the "SEC"), the Company was not in compliance with Nasdaq's continued listing requirements under Nasdaq Listing Rule 5250(c)(1). The Notice has no immediate effect on the listing of the Company

      6/13/24 4:15:00 PM ET
      $ACAB
      Blank Checks
      Finance
    • Abpro Announces Filing of Registration Statement on Form S-4 in Connection with Business Combination Agreement with Atlantic Coastal Acquisition Corp. II

      WOBURN, Mass. and NEW YORK, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Abpro Corporation ("Abpro"), a biotech company with the mission of improving the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies, and Atlantic Coastal Acquisition Corp. II (NASDAQ:ACAB), a special purpose acquisition company ("Atlantic Coastal"), today announced the filing of a registration statement on Form S-4 (the "Registration Statement") with the U.S. Securities and Exchange Commission ("SEC") on January 19, 2024, which includes a preliminary proxy statement and prospectus in connection with its proposed business combination. Upon the closing of the proposed business

      1/22/24 8:00:00 AM ET
      $ACAB
      Blank Checks
      Finance
    • Abpro to Become Publicly Traded via Merger with Atlantic Coastal Acquisition Corp. II

      Abpro is a biotechnology company specializing in the development of next-generation antibody therapies intended to improve the lives of those with life-threatening diseases. The transaction values Abpro at $725 million and will help advance Abpro's drug pipeline to clinical trials. Abpro Corporation ("Abpro"), a biotechnology company with the mission of improving the lives of those facing severe and life-threatening diseases with next-generation antibody therapies, and Atlantic Coastal Acquisition Corp. II (NASDAQ:ACAB), a special purpose acquisition corporation ("Atlantic Costal"), today announced a term sheet to enter into a definitive business combination, which was entered into o

      9/21/23 4:00:00 PM ET
      $ACAB
      Blank Checks
      Finance

    $ACAB
    SEC Filings

    See more
    • SEC Form NT 10-Q filed by Atlantic Coastal Acquisition Corp. II

      NT 10-Q - Abpro Holdings, Inc. (0001893219) (Filer)

      11/15/24 4:05:03 PM ET
      $ACAB
      Blank Checks
      Finance
    • Atlantic Coastal Acquisition Corp. II filed SEC Form 8-K: Regulation FD Disclosure

      8-K - Abpro Holdings, Inc. (0001893219) (Filer)

      11/13/24 5:21:02 PM ET
      $ACAB
      Blank Checks
      Finance
    • SEC Form 25-NSE filed by Atlantic Coastal Acquisition Corp. II

      25-NSE - Atlantic Coastal Acquisition Corp. II (0001893219) (Subject)

      11/12/24 4:31:03 PM ET
      $ACAB
      Blank Checks
      Finance

    $ACAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Atlantic Coastal Acquisition Corp. II (Amendment)

      SC 13G/A - Atlantic Coastal Acquisition Corp. II (0001893219) (Subject)

      2/7/24 1:53:24 PM ET
      $ACAB
      Blank Checks
      Finance
    • SEC Form SC 13G/A filed by Atlantic Coastal Acquisition Corp. II (Amendment)

      SC 13G/A - Atlantic Coastal Acquisition Corp. II (0001893219) (Subject)

      1/19/24 4:17:41 PM ET
      $ACAB
      Blank Checks
      Finance
    • SEC Form SC 13D filed by Atlantic Coastal Acquisition Corp. II

      SC 13D - Atlantic Coastal Acquisition Corp. II (0001893219) (Subject)

      4/20/23 6:01:50 AM ET
      $ACAB
      Blank Checks
      Finance

    $ACAB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Abpro Bio International, Inc. claimed ownership of 16,507,334 shares (SEC Form 3)

      3 - Abpro Holdings, Inc. (0001893219) (Issuer)

      11/18/24 9:00:34 PM ET
      $ACAB
      Blank Checks
      Finance
    • SEC Form 3 filed by new insider Mcdonald Ian

      3 - Abpro Holdings, Inc. (0001893219) (Issuer)

      11/18/24 8:52:41 PM ET
      $ACAB
      Blank Checks
      Finance
    • Co-CEO & Chairman Suk Jin Wook (Miles) was granted 91,900 shares (SEC Form 4)

      4 - Abpro Holdings, Inc. (0001893219) (Issuer)

      11/15/24 9:34:52 PM ET
      $ACAB
      Blank Checks
      Finance